<DOC>
	<DOCNO>NCT01408602</DOCNO>
	<brief_summary>This study treat moderate severe rheumatoid arthritis MRC375 ( either 75 mg 3 time day , 150 mg 3 time day placebo 3 time day ) patient 18 year age older currently low dos methotrexate stop treatment current RA medication enter study . Safety MRC375 also evaluate . There 8 clinic visit 24 week .</brief_summary>
	<brief_title>A Study Two Doses MRC375 Moderate Severe Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled study ass safety efficacy MRC375 75 mg 150 mg match placebo ( take tid meal light snack ) patient moderate severe RA . Patients randomize one follow study arm 24 week : - Treatment 1 , Placebo : 2 tablet take tid - Treatment 2 , MRC375 : 1 tablet 75 mg tetracycline HCL plus 1 matching placebo tablet take tid . Total daily dose = 225 mg. - Treatment 3 , MRC375 : 2 tablet 75 mg tetracycline HCL take tid . Total daily dose = 450 mg. Study medication take within 30 minute meal light snack ( either ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>1 . Is 18 year age 2 . Is diagnosed moderate severe adult onset RA &gt; = 6 month duration , defined 1987 ACR classification criterion 3 . Has moderate severe RA define : ≥4 tender joints/painful ( 28 joint count ) screen ≥4 swollen joint ( 28 joint count ) screen 4 . Has Health Assessment Questionnaire ( HAQ ) &gt; 0 5 . Has physician global assessment ( Likert scale ) &gt; 0 6 . Has patient global assessment pain ( Likert scale ) &gt; 0 7 . Has patient assessment pain ( Likert scale ) &gt; 0 8 . Has stable dos follow allowable medication study , applicable : Stable dose NSAIDs analgesic least 2 week prior administration study drug regulatory approve dos Stable dose methotrexate 7.5 mg 25 mg/day weekly least 6 week prior administration study drug ( change dose regimen 4 week prior screen ) Stable dose hydroxychloroquine either monotherapy combination methotrexate 8 week prior administration study drug 9 . Is nonpregnant , nonlactating female postmenopausal , naturally surgically sterile , agree use effective contraceptive method throughout course study . Postmenopausal define least 12 month natural spontaneous amenorrhea 10 . If female childbearing potential , must agree use one follow acceptable birth control method : Surgically sterile ( bilateral tubal ligation surgery least 6 week prior screen , hysterectomy , bilateral oophorectomy ) ; Intrauterine device ( IUD ) place least 3 month prior first dose study drug ; Abstinence ( sexual intercourse ) ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Stable hormonal contraceptive least 3 month prior study study completion 11 . If female childbearing potential , negative serum hCG pregnancy test screen 12 . Is able swallow whole tablet orally administer medication 13 . Is able understand provide sign informed consent . 1 . Has diagnose inflammatory arthritis ( eg , psoriatic arthritis ) 2 . Has secondary type arthritis ( eg , osteoarthritis ) would interfere study evaluation 3 . Has take follow drug within timeframe specify : Infliximab , etanercept , adalimumab , abatacept , biological therapy ( except rituximab ) Within 12 week prior administration study drug ; Rituximab Within 12 month prior administration study drug ; Diseasemodifying antirheumatic drug ( DMARDs ) antirheumatic therapy specify include limited : sulfasalazine , gold , leflunomide , penicillamine , dapsone , azathioprine , 6mercaptopurine , chlorambucil , cyclophosphamide , cyclosporin , mycophenolate mofetil Within 12 week prior administration study drug ; Any steroid ( glucocorticoid ) ; glucocorticoid must discontinue least 4 week prior administration study drug . Intraarticular , intramuscular , intravenous glucocorticoid must give least 6 week prior administration study drug . Note : Use probiotic allow NOT exclusion criterion . 4 . Has uncontrolled symptom fibromyalgia sufficient symptom require treatment ( NOTE : patient stable dose treatment symptom fibromyalgia ≥ 4 week allow study . ) 5 . Has history allergic reaction tetracycline relate drug 6 . Had major surgery trauma within 28 day prior screen 7 . Is concurrently use minocycline doxycycline ( washout 4 week require administration study drug ) 8 . Patients chronic antibiotic antibiotic GI infection ( Clostridium difficile ) 9 . Has clinically significant ECG abnormalities 10 . Has clinically significant abnormal laboratory test result find medical screen include : AST ALT &gt; 2 x upper limit normal serum creatinine &gt; 2.0 mg/dL 11 . Has clinically significant history presence gastrointestinal pathology ( eg , chronic diarrhea , inflammatory bowel disease , acute diverticulitis ) , irritable bowel syndrome , unresolved gastrointestinal symptom ( eg . diarrhea , vomit , symptom acute diverticulitis ) , liver kidney disease , gastric bypass , gastric stapling , use LapBand® , condition know might interfere absorption , distribution , metabolism , excretion drug 12 . Has historical active neurological , endocrine , cardiovascular , pulmonary , hematological , psychiatric , metabolic disease consider clinically significant Investigator 13 . Has know history HIV , hepatitis B C ( patient positive hepatitis B serology due prior vaccination allow study ) 14 . Has active malignancy type history malignancy . Patients history successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma ( ie . non melanoma skin cancer ) and/or localized carcinoma situ cervix eligible . Patients history malignancy treat evidence recurrence least 5 year study enrollment also eligible . 15 . Has difficulty swallow tablet 16 . Is ACR Functional Class IV ( limited ability perform usual selfcare , vocational , avocational activity ) 17 . Has know suspect pregnancy , plan pregnancy , lactation ( female patient ) 18 . Has clinically significant mental illness ( determined Investigator ) 19 . Has history last 2 year current evidence abuse illicit drug , prescription medication , alcohol , opinion Investigator , would interfere adherence study requirement . Has exposure investigational agent within 30 day prior study entry . 20 . Was previously enrol study 21 . Has recent history bacterial intestinal tract infection ( gastroenteritis , colitis , diverticulitis , appendicitis ) 22 . Has condition Investigator believe would interfere ability provide inform consent comply study instruction , might confound interpretation study result put patient undue risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>